Recombinant Anti-CHD1L antibody [EPR14515(2)] (ab197019)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR14515(2)] to CHD1L
- Suitable for: Flow Cyt (Intra), WB, IHC-P, ICC/IF, IP
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-CHD1L antibody [EPR14515(2)]
See all CHD1L primary antibodies -
Description
Rabbit monoclonal [EPR14515(2)] to CHD1L -
Host species
Rabbit -
Tested applications
Suitable for: Flow Cyt (Intra), WB, IHC-P, ICC/IF, IPmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: HeLa and A549 cell lysates. IHC-P: Human hepatocellular carcinoma and mouse liver tissues. ICC/IF: HeLa cells. IP: 293 whole cell extract.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR14515(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab197019 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt (Intra) |
1/520.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB |
1/5000. Predicted molecular weight: 101 kDa.
|
|
IHC-P |
1/250. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
|
ICC/IF |
1/500.
|
|
IP |
1/30.
|
Notes |
---|
Flow Cyt (Intra)
1/520. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
WB
1/5000. Predicted molecular weight: 101 kDa. |
IHC-P
1/250. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
ICC/IF
1/500. |
IP
1/30. |
Target
-
Function
DNA helicase which plays a role in chromatin-remodeling following DNA damage. Targeted to sites of DNA damage through interaction with poly(ADP-ribose) and functions to regulate chromatin during DNA repair. Able to catalyze nucleosome sliding in an ATP-dependent manner. Helicase activity is strongly stimulated upon poly(ADP-ribose)-binding. -
Tissue specificity
Frequently overexpressed in hepatomacellular carcinomas. -
Sequence similarities
Belongs to the SNF2/RAD54 helicase family.
Contains 1 helicase ATP-binding domain.
Contains 1 helicase C-terminal domain.
Contains 1 Macro domain. -
Domain
The macro domain mediates non-covalent poly(ADP-ribose)-binding and recruitment to DNA damage sites. -
Cellular localization
Nucleus. Localizes at sites of DNA damage. Probably recruited to DNA damage sites by PARylated PARP1. - Information by UniProt
-
Database links
- Entrez Gene: 9557 Human
- Entrez Gene: 68058 Mouse
- Omim: 613039 Human
- SwissProt: Q86WJ1 Human
- SwissProt: Q9CXF7 Mouse
- Unigene: 191164 Human
- Unigene: 41447 Mouse
-
Alternative names
- ALC1 antibody
- Amplified in liver cancer 1 antibody
- Amplified in liver cancer protein 1 antibody
see all
Images
-
All lanes : Anti-CHD1L antibody [EPR14515(2)] (ab197019) at 1/5000 dilution
Lane 1 : HeLa (Human epithelial cells from cervix adenocarcinoma) cell lysate
Lane 2 : A549 (Human lung carcinoma) cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 101 kDa
Observed band size: 101 kDaBlocking/Dilution buffer: 5% NFDM/TBST.
-
Immunohistochemical analysis of paraffin-embedded Human hepatocellular carcinoma tissue labeling CHD1L with ab197019 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Nuclear and weakly cytoplasm staining on Human hepatocellular carcinoma tissue is observed. Counter stained with Hematoxylin.
Negative control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin-embedded mouse liver tissue labeling CHD1L with ab197019 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Nuclear and weakly cytoplasm staining on mouse liver tissue is observed. Counter stained with Hematoxylin.
Negative control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (Human epithelial cells from cervix adenocarcinoma) cells labeling CHD1L with ab197019 at 1/500 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/500 dilution (green). Nuclear and weakly cytoplasm staining on HeLa cell line was observed. The nuclear counter stain is DAPI (blue). Tubulin is detected with ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution and ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution (red).
The negative controls are as follows:
-ve control 1: ab197019 at 1/500 dilution followed by ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution.
-ve control 2: ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution followed by ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/500 dilution. -
Intracellular flow cytometric analysis of HeLa (Human epithelial cells from cervix adenocarcinoma)cells labeling CHD1L with ab197019 at 1/520 dilution (red) compared with a rabbit monoclonal IgG isotype control (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (FITC) at 1/150 dilution was used as the secondary antibody.
-
CHD1L was immunoprecipitated from 293 (Human embryonic kidney) whole cell extract with ab197019 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab197019 at 1/1000 dilution. Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG, was used as secondary antibody at 1/1500 dilution. Lane 1: 293 whole cell extract (Input) 10 µg. Lane 2: ab197019 IP in 293 whole cell extract. Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab197019 in 293 whole cell extract.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (3)
ab197019 has been referenced in 3 publications.
- Wang G et al. CHD1L prevents lipopolysaccharide-induced hepatocellular carcinomar cell death by activating hnRNP A2/B1-nmMYLK axis. Cell Death Dis 12:891 (2021). PubMed: 34588420
- Li Y et al. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-?B axis in human non-small-cell lung cancer. Cell Death Dis 10:99 (2019). PubMed: 30718500
- Li S et al. CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma. Oncol Rep 42:657-669 (2019). PubMed: 31173252